Catalog No.
DHB65401
Expression system
Mammalian Cells
Species reactivity
Human
Host species
Humanized
Isotype
IgG1-kappa
Clonality
Monoclonal
Target
Sodium/phosphate cotransporter 2B, Na(+)-dependent phosphate cotransporter 2B, Na(+)/Pi cotransporter 2B, Sodium-dependent phosphate transport protein 2B, NaPi3b, NaPi-2b, SLC34A2, Solute carrier family 34 member 2, Sodium-phosphate transport protein 2B
Concentration
1 mg/ml
Endotoxin level
Please contact with the lab for this information.
Purity
>95% as determined by SDS-PAGE.
Purification
Protein A/G purified from cell culture supernatant.
Accession
O95436
Applications
Research Grade Biosimilar
Form
Liquid
Storage buffer
0.01M PBS, pH 7.4.
Stability and Storage
Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.
Alternative Names
DNIB0600A (conjugate), MNIB2126A (non conjugate), CAS: 1615697-16-9
Clone ID
Lifastuzumab
Anti-NaPi2b antibody-drug conjugate lifastuzumab vedotin (DNIB0600A) compared with pegylated liposomal doxorubicin in patients with platinum-resistant ovarian cancer in a randomized, open-label, phase II study, PMID: 29401246
Phase 1b study of anti-NaPi2b antibody-drug conjugate lifastuzumab vedotin (DNIB0600A) in patients with platinum-sensitive recurrent ovarian cancer, PMID: 32534811
Phase Ia Study of Anti-NaPi2b Antibody-Drug Conjugate Lifastuzumab Vedotin DNIB0600A in Patients with Non-Small Cell Lung Cancer and Platinum-Resistant Ovarian Cancer, PMID: 31540980
Phase 1b study of anti-NaPi2b antibody-drug conjugate lifastuzumab vedotin (DNIB0600A) in patients with platinum-sensitive recurrent ovarian cancer., PMID:32534811
Phase Ia Study of Anti-NaPi2b Antibody-Drug Conjugate Lifastuzumab Vedotin DNIB0600A in Patients with Non-Small Cell Lung Cancer and Platinum-Resistant Ovarian Cancer., PMID:31540980
Anti-NaPi2b antibody-drug conjugate lifastuzumab vedotin (DNIB0600A) compared with pegylated liposomal doxorubicin in patients with platinum-resistant ovarian cancer in a randomized, open-label, phase II study., PMID:29401246
For research use only. Not for human or drug use.
